Engimmune Therapeutics Raises Chf 15.5 Million In Seed Financing To Develop Novel T-Cell Receptor Therapeutics
Engimmune Therapeutics Raises Chf 15.5 Million In Seed Financing To Develop Novel T-Cell Receptor Therapeutics
05/03/22, 3:00 AM
Location
baselRound Type
seed
Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced today the completion of a CHF 15.5 million (EUR 15.2 m / USD 16.7 m) seed financing round, co-led by Pureos Bioventures and Novo Holdings.
Company Info
Location
basel, basel city, switzerland
Additional Info
Engimmune Therapeutics is a technology platform and product-based company using cutting-edge technologies to engineer highly potent and specific T cell receptor (TCR) therapies. By applying proprietary platform technologies combining genome editing, functional high-throughput screening, deep sequencing and machine learning, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics. Spinning out from ETH Zurich and with support from BaseLaunch, the Swiss life sciences incubator, the Company raised a CHF 15.5 million seed series from leading biotech investors, Pureos Bioventures and Novo Holdings. For more information, please visit www.engimmune.com.